Promega builds plant to produce regulated products
Including sample preparation systems and reagents
The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.
‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.
Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.
Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)
Read moreStandardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)
Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)
As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
Analysis
Countable Labs and Promega to facilitate end-to end biological sample preparation and rare variant detection
Joint offering creates state-of-the-art workflow uniting Promega’s fast and reliable nucleic acid extraction instrumentation with Countable Labs’ accurate and easy-to-use Countable PCR technology to deliver accuracy across research
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Manufacturing
What makes a GMP quality system effective in day-to-day pharmaceutical manufacturing?
Your quality system may have a procedure for almost everything: reporting a deviation, reviewing a batch record, changing equipment settings and training the people who operate it. But having a procedure and getting a useful answer from it are two different things